Clinical trial · Interventional
Evaluation of Pancreatic Duct Stenting in Patients With Pancreatic Pseudocysts.
Randomized Multicenter Study on Pancreatic Duct Stenting in Disrupted or Obstructed Ducts in Context With Endoscopic Treatment of Pancreatic Pseudocysts.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No appropriate participants
Summary
Brief summary (as posted)
The disruption of the pancreatic duct seems to be a major cause pseudocyst formation and persistence in patients suffering from acute/chronic pancreatitis. No prospective randomized studies have been conducted on the influence of pancreatic duct stenting for the patients' benefits and recurrence rates. The aim fo this study is therefore to evaluate prospectively in a randomized, controlled fashion in patients wit pancreatic pseudocysts, wether pancreatic duct stenting of a disrupted pancreatic duct is beneficial in terms of quicker clinical recovery and avoidance of recurrence of pancreatic pseudocysts.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Acute Pancreatitis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pancreatic duct stenting | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- No stenting
- description
- Control group, no stenting of the pancreatic duct in case of a disrupted duct
- type
- ACTIVE_COMPARATOR
- label
- Pancreatic duct stenting
- description
- in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting in this arm
- interventionNames
- Procedure: pancreatic duct stenting
Primary outcomes (1)
- measure
- Recurrence of pancreatic pseudocyst
- timeFrame
- two years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * pancreatic pseudocyst, at least 6 cm in diameter * symptomatic pancreatic pseudocyst * increasing size of pancreatic pseudocyst within 6 weeks Exclusion Criteria: * Pregnancy * Age less than 18 years * Postoperative status preventing access to papilla * Allergy to contrast preventing from ERP * Missing informed consent to study * PTT above 1.5 times of normal, unless substituted * Platelet count less than 50.000/µl, unless substituted * Pancreatic ascites or fistula * Life expectancy less than 2 years * Percutaneously drained cysts are not part of the study
References
Publications (0)
Data not yet available